Ozkan Hasan, Akar Tarik, Köklü Seyfettin, Coban Sahin
Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkey.
Pancreatology. 2006;6(4):268-72. doi: 10.1159/000092687. Epub 2006 Apr 19.
BACKGROUND/AIMS: RCAS1 is a novel tumor marker, and there are no sufficient data about the utility of this antigen as a serum tumor marker and about its tumor specificity. We aimed at measuring the serum levels of RCAS1 in patients with pancreatic cancer and at determining its diagnostic efficacy.
Sera collected from patients with pancreas adenocarcinomas (39 cases) and benign biliary and pancreatic diseases (19 cases) and from healthy volunteers (13 cases) were analyzed for RCAS1 and the results compared with CA19-9. The relation between serum RCAS1 and tumor stage was also evaluated.
The serum RCAS1 levels exceeded the normal limit in 92.3, 26.3, and 23.0% of the patients with pancreatic cancer and benign biliary and pancreatic diseases and healthy volunteers, respectively. RCAS1 had a specificity similar to that of CA19-9 in pancreatic cancer, whereas RCAS1 had a higher sensitivity (p < 0.05). Both tumor markers had similar predictive values of positive and negative tests for pancreatic cancer. The RCAS1 level was less influenced than the CA19-9 level by biliary stenoses. The median serum levels of RCAS1 increased, as the tumor stage increased.
RCAS1 is a valuable serum marker for the diagnosis of pancreatic cancer. The RCAS1 and CA19-9 levels increase the diagnostic efficiency of each other in pancreatic cancer.
背景/目的：RCAS1是一种新型肿瘤标志物，关于这种抗原作为血清肿瘤标志物的效用及其肿瘤特异性，目前尚无足够数据。我们旨在测量胰腺癌患者血清中RCAS1的水平，并确定其诊断效能。
分析从胰腺腺癌患者（39例）、良性胆道和胰腺疾病患者（19例）以及健康志愿者（13例）采集的血清中的RCAS1，并将结果与CA19-9进行比较。还评估了血清RCAS1与肿瘤分期之间的关系。
胰腺癌患者、良性胆道和胰腺疾病患者以及健康志愿者中，血清RCAS1水平超过正常上限的比例分别为92.3%、26.3%和23.0%。在胰腺癌中，RCAS1的特异性与CA19-9相似，而RCAS1的敏感性更高（p<0.05）。两种肿瘤标志物对胰腺癌的阳性和阴性检测预测值相似。与CA19-9水平相比，RCAS1水平受胆道狭窄的影响较小。随着肿瘤分期增加，RCAS1的血清中位数水平升高。
RCAS1是诊断胰腺癌的一种有价值的血清标志物。在胰腺癌中，RCAS1和CA19-9水平可相互提高诊断效率。
